AU2003299984A1 - Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof - Google Patents

Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof Download PDF

Info

Publication number
AU2003299984A1
AU2003299984A1 AU2003299984A AU2003299984A AU2003299984A1 AU 2003299984 A1 AU2003299984 A1 AU 2003299984A1 AU 2003299984 A AU2003299984 A AU 2003299984A AU 2003299984 A AU2003299984 A AU 2003299984A AU 2003299984 A1 AU2003299984 A1 AU 2003299984A1
Authority
AU
Australia
Prior art keywords
antibody
seq
multivalent
antibodies
construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003299984A
Other languages
English (en)
Inventor
Veronique Bailly
Jeffrey L. Browning
Ellen Garber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of AU2003299984A1 publication Critical patent/AU2003299984A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003299984A 2002-12-20 2003-12-22 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof Abandoned AU2003299984A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43515402P 2002-12-20 2002-12-20
US60/435,154 2002-12-20
PCT/US2003/041393 WO2004058191A2 (en) 2002-12-20 2003-12-22 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AU2003299984A1 true AU2003299984A1 (en) 2004-07-22

Family

ID=32682169

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003299984A Abandoned AU2003299984A1 (en) 2002-12-20 2003-12-22 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Country Status (8)

Country Link
US (1) US20060104971A1 (enExample)
EP (1) EP1583503A4 (enExample)
JP (1) JP2006515750A (enExample)
CN (1) CN100473664C (enExample)
AU (1) AU2003299984A1 (enExample)
CA (1) CA2511013A1 (enExample)
NO (1) NO20053530L (enExample)
WO (1) WO2004058191A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
SK5672003A3 (en) * 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi
CA2529945A1 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
WO2005092927A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
AU2014200661B2 (en) * 2006-06-12 2016-06-30 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2016231617B2 (en) * 2006-06-12 2018-08-23 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CA2666934A1 (en) * 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
EP2167130A2 (en) * 2007-07-06 2010-03-31 Trubion Pharmaceuticals, Inc. Binding peptides having a c-terminally disposed specific binding domain
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
KR100967623B1 (ko) * 2008-02-22 2010-07-05 전남대학교산학협력단 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2013166099A1 (en) * 2012-05-01 2013-11-07 Glaxosmithkline Llc Novel antibodies
WO2014118578A1 (en) * 2013-02-04 2014-08-07 University Of Huddersfield Composition comprising a tnfr agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma.
TWI700295B (zh) * 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
JP2018503399A (ja) * 2015-01-14 2018-02-08 コンパス セラピューティクス リミテッド ライアビリティ カンパニー 多特異性免疫調節抗原結合構築物
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHOD
CN120535653A (zh) 2018-10-19 2025-08-26 明尼苏达大学董事会 Nk接合子分子及其使用方法
CA3164226A1 (en) * 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
WO2022117572A2 (en) 2020-12-02 2022-06-09 Oncurious Nv An ltbr agonist in combination therapy against cancer
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669941A (en) * 1898-12-17 1901-03-12 Electric Axle Light & Power Company Electric switch.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69334224D1 (de) * 1992-12-04 2008-07-17 Biogen Idec Inc Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
DE69632681T2 (de) * 1995-01-26 2005-06-09 Biogen, Inc., Cambridge Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
MXPA02010011A (es) * 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
SI1295129T1 (sl) * 2000-06-30 2010-08-31 Innogenetics Nv Diferencialna diagnoza nevroloških bolezni
AU8678501A (en) * 2000-08-24 2002-03-04 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
SK5672003A3 (en) * 2000-10-13 2003-10-07 Biogen Inc Humanized anti-LT-beta-R antibodies
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7642242B2 (en) * 2002-03-05 2010-01-05 Genentech, Inc. PRO34128 polypeptides
NZ537965A (en) * 2002-07-01 2008-04-30 Biogen Idec Inc Humanized anti-lymphotoxin beta receptor antibodies
PL377611A1 (pl) * 2002-12-20 2006-02-06 Biogen Idec Ma Inc. Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi

Also Published As

Publication number Publication date
WO2004058191A3 (en) 2005-12-29
JP2006515750A (ja) 2006-06-08
CN1798765A (zh) 2006-07-05
US20060104971A1 (en) 2006-05-18
NO20053530L (no) 2005-09-20
EP1583503A4 (en) 2006-08-09
CA2511013A1 (en) 2004-07-15
EP1583503A2 (en) 2005-10-12
NO20053530D0 (no) 2005-07-19
CN100473664C (zh) 2009-04-01
WO2004058191A2 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
US20060104971A1 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
JP2006515750A5 (enExample)
US7947271B2 (en) Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents
US20060134102A1 (en) Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
KR101749770B1 (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 시클로포스파미드를 함유하는 항종양 조합물
KR101733252B1 (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물
CN113004391A (zh) 结合nkg2d、cd16和egfr、ccr4或pd-l1的蛋白质
CA3091140A1 (en) Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer
JP2012515217A (ja) ベンダムスチンおよび抗−ｃｄ２０抗体の組合せを用いた癌治療
KR20110091785A (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 빈크리스틴을 함유하는 항종양 조합물
TW200416044A (en) Humanized anti-lymphotoxin β receptor antibodies
JP2006513225A5 (enExample)
WO2018081898A1 (en) Improvements in cd47 blockade therapy by hdac inhibitors
CN115697419A (zh) 多聚体抗dr5结合分子与癌症疗法组合治疗癌症的用途
US20090175866A1 (en) Treatment of b-cell malignancies
TW202408571A (zh) 使用抗ｔｉｇｉｔ抗體治療淋巴瘤之方法
CN112672759B (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
WO2021098749A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with radiation
EP2236139A1 (en) Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
CN116059377A (zh) 抗ox40抗体在联合用药中的应用
TW202440151A (zh) Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法
CA3258963A1 (en) POLYTHERAPY INCLUDING A SIRP ALPHA FUSION PROTEIN AND AN ANTI-CD19 ANTIBODY FOR CANCER TREATMENT
CA3217814A1 (en) Enhancement of cd47 blockade therapy with dhfr inhibitors
MXPA06010891A (en) Receptor coupling agents and therapeutic uses thereof
Zhang et al. Therapeutic antibodies in clinical use and leading clinical candidates

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application